Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M86,371Revenue $M19,616Net Margin (%)11.2Altman Z-Score4.0
Enterprise Value $M90,479EPS $2.2Operating Margin %16.0Piotroski F-Score4
P/E(ttm)37.5Beneish M-Score-2.6Pre-tax Margin (%)13.9Higher ROA y-yN
Price/Book5.310-y EBITDA Growth Rate %10.8Quick Ratio1.1Cash flow > EarningsY
Price/Sales4.35-y EBITDA Growth Rate %-6.0Current Ratio1.4Lower Leverage y-yN
Price/Free Cash Flow35.1y-y EBITDA Growth Rate %-32.9ROA % (ttm)6.2Higher Current Ratio y-yN
Dividend Yield %2.5PEG--ROE % (ttm)13.0Less Shares Outstanding y-yY
Payout Ratio %96.0Shares Outstanding M1,110ROIC % (ttm)13.7Gross Margin Increase y-yN

Gurus Latest Trades with LLY

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
LLYVanguard Health Care Fund 2015-03-31 Add0.45%$68.41 - $76.36
($71.19)
$ 77.959%Add 13.24%24,892,160
LLYCharles Brandes 2015-03-31 Reduce-0.06%$68.41 - $76.36
($71.19)
$ 77.959%Reduce 36.80%107,025
LLYKen Fisher 2015-03-31 Add0.03%$68.41 - $76.36
($71.19)
$ 77.959%Add 37.46%795,909
LLYHOTCHKIS & WILEY 2015-03-31 Add0.01%$68.41 - $76.36
($71.19)
$ 77.959%Add 0.70%3,968,039
LLYJoel Greenblatt 2015-03-31 Sold Out -0.0031%$68.41 - $76.36
($71.19)
$ 77.959%Sold Out0
LLYDodge & Cox 2015-03-31 Reduce$68.41 - $76.36
($71.19)
$ 77.959%Reduce 7.10%36,234
LLYMario Gabelli 2015-03-31 Reduce$68.41 - $76.36
($71.19)
$ 77.959%Reduce 1.76%111,800
LLYCharles Brandes 2014-12-31 Reduce-1.85%$61.9 - $72.83
($67.53)
$ 77.9515%Reduce 92.65%169,348
LLYRichard Pzena 2014-12-31 Sold Out -0.15%$61.9 - $72.83
($67.53)
$ 77.9515%Sold Out0
LLYKen Fisher 2014-12-31 Add0.07%$61.9 - $72.83
($67.53)
$ 77.9515%Add 383.26%578,992
LLYCharles Brandes 2014-09-30 Reduce-0.29%$60.35 - $66.59
($63.3)
$ 77.9523%Reduce 14.27%2,303,062
LLYHOTCHKIS & WILEY 2014-09-30 Reduce-0.12%$60.35 - $66.59
($63.3)
$ 77.9523%Reduce 10.92%4,321,666
LLYGeorge Soros 2014-09-30 Sold Out -0.02%$60.35 - $66.59
($63.3)
$ 77.9523%Sold Out0
LLYDavid Dreman 2014-09-30 Reduce-0.02%$60.35 - $66.59
($63.3)
$ 77.9523%Reduce 84.40%900
LLYKen Fisher 2014-09-30 Add0.02%$60.35 - $66.59
($63.3)
$ 77.9523%Add 2742.47%119,810
LLYJoel Greenblatt 2014-09-30 Reduce$60.35 - $66.59
($63.3)
$ 77.9523%Reduce 27.37%5,628
LLYDodge & Cox 2014-09-30 Add$60.35 - $66.59
($63.3)
$ 77.9523%Add 20.38%42,464
LLYHOTCHKIS & WILEY 2014-06-30 Add0.73%$58.21 - $63.1
($59.62)
$ 77.9531%Add 199.70%4,851,480
LLYVanguard Health Care Fund 2014-06-30 Reduce-0.15%$58.21 - $63.1
($59.62)
$ 77.9531%Reduce 3.98%21,982,700
LLYGeorge Soros 2014-06-30 Buy 0.02%$58.21 - $63.1
($59.62)
$ 77.9531%New holding50,441
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

LLY is held by these investors:


News about LLY:

Articles On GuruFocus.com
Abbvie Inc. Dividend Stock Analysis May 26 2015 
Biogen Making A Breakthrough In Treating Alzheimer’s May 02 2015 
MannKind Looks Good For Long Term Investors Apr 29 2015 
What Are The Intrinsic Factors Contributing To Pfizer’s Stock Movement? Mar 27 2015 
Eli Lilly Inks Major Deal In China To Develop Oncology Segment Mar 23 2015 
Box Inc. Declares Mixed Bag Q4 Results for 2015 Mar 13 2015 
Primecap Management's Annual Shareholder Letter 2014 Mar 09 2015 
FDA Approves Sanofi’s New Diabetes Drug Feb 27 2015 
Feeling Good With This Med Company Jan 20 2015 
Sarah Ketterer Dives in when Others Pull Out Nov 14 2014 

More From Other Websites
FDA panel to discuss Lilly's lung cancer drug approval Jun 02 2015
Elanco Announces Comprehensive Antibiotic Stewardship Plan, Significant Research Effort Jun 02 2015
AstraZeneca Presents Data at ASCO; Inks Deal with Eli Lilly - Analyst Blog Jun 01 2015
Novel government cancer study will test precision medicine Jun 01 2015
Novel government cancer study will test precision medicine Jun 01 2015
Facebook and Google on privacy, Bernanke on interest rates and income inequality Jun 01 2015
AstraZeneca CEO: Transforming cancer treatments Jun 01 2015
BMY hit on disappointing drug trial May 29 2015
Buying into biotech: 5 trades on 3 stocks May 29 2015
At ASCO: Bristol, Merck Drugs Shrink Several Tumor Types May 29 2015
Jim Cramer's Stop Trading: Lilly's AstraZeneca Partnership Is a ‘Brilliant’ Move May 29 2015
Lilly to Participate in Goldman Sachs Global Healthcare Conference May 29 2015
Lilly to Participate in Goldman Sachs Global Healthcare Conference May 29 2015
Cramer's Stop Trading: Eli Lilly May 29 2015
Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors May 29 2015
Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors May 29 2015
LILLY ELI & CO Files SEC form 8-K, Other Events, Financial Statements and Exhibits May 29 2015
AstraZeneca and Lilly to test new cancer drug combination May 29 2015
AstraZeneca and Lilly to test new cancer drug combination May 29 2015
AstraZeneca and Lilly to collaborate on Immuno-oncology combination clinical trial in solid tumours May 29 2015

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK